share_log

康方生物(09926.HK)：AK112-303 / HARMONi-2已作为LBA入选2024 WCLC 将在全体会议主席专题研讨会上口头报告

Akeso (09926.HK): AK112-303/HARMONi-2 have been selected as LBA for the 2024 WCLC and will be orally reported at the plenary session and the chairman's special symposium.

Gelonghui Finance ·  19:46

Ge Longhui, August 12, 丨 Kang Fang Biology (09926.HK) announced that the results of the Phase III clinical study (AK112 -303/Harmoni2) of the world's first bispecific antibody (EVO, PD-1/VEGF) single-drug first-line treatment of locally advanced or metastatic non-small cell lung cancer (“NSCLC”) with positive PD-L1 expression (PD-L1 TPS 51%) (“NSCLC”) were selected by the company as Lbreaking Abstract (LBA) Complete data for the 2024 World Lung Cancer Conference (WCLC) hosted by the International Association for Lung Cancer Research (IASLC) will be presented in the form of an oral report by Professor Zhou Caicun, the principal investigator (PI) of this clinical trial, at the Presidential Symposium (Presidential Symposium). Evosil became the first and only drug in the world to prove that efficacy was significantly superior to pabolizumab in a single-drug head-to-head phase III clinical study. The company has recently submitted a marketing application (s NDA) for this new indication to the China National Drug Administration (“NMPA”).

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment